Received Sep 19, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | UNK | — | — |
experiencing pronounced effects on his osteoarthritis including severe pain; experiencing pronounced effects on his osteoarthritis including severe pain; This is a spontaneous report received from a Consumer or other non HCP from medical information team. A male patient received BNT162b2 omicron (lp.8.1) (COMIRNATY (2025-2026 FORMULA)), in 2025 as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "osteoarthritis" (ongoing). The patient's concomitant medications were not reported. Vaccination history included: Comirnaty (DOSE 1), for COVID-19 immunization; Comirnaty (DOSE 2), for COVID-19 immunization; Comirnaty (DOSE 3), for COVID-19 immunization; Comirnaty (DOSE 4), for COVID-19 immunization. The following information was reported: OSTEOARTHRITIS (non-serious), CONDITION AGGRAVATED (non-serious) all with onset 2025, outcome "unknown" and all described as "experiencing pronounced effects on his osteoarthritis including severe pain". Additional information: the patient reported that he received all previous COVID vaccinations with the Pfizer vaccine. The patient stated he had five vaccinations. The patient stated he was experiencing pronounced effects on his osteoarthritis including severe pain. No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.
Osteoarthritis